Table 3. Risk for all-cause mortality according to age-corrected RTL quartiles in B12 low, mid-range and high (n=2970, only subjects in whom the measurements of B12 and RTL were complete).
| (A) 1st quartile of B12 (n=756) | |||||||
| Age-corrected RTL quartiles | Nr. of deceased(%) / alive (%) patients | Model 1 HR (95%CI) | P | Model 2 HR (95%CI) | P | Model 3 HR (95%CI) | P |
| 1st (<0.0140) (LB12ST) (n=193) | 75 (39%) / 118 (61%) | Ref. | Ref. | Ref. | |||
| 2nd - 3rd(0.0141-0.0509) (n=389) | 131 (34%) / 258 (66%) | 0.84 (0.63-1.12) | 0.232 | 0.78 (0.56-1.08) | 0.137 | 0.77 (0.54-1.09) | 0.137 |
| 4th (>0.0510) (LB12LT) (n=174) | 42 (24%) / 132 (76%) | 0.57 (0.39-0.83) | 0.004 | 0.57 (0.37-0.87) | 0.009 | 0.75 (0.48-1.17) | 0.211 |
| (B) Mid-range B12 (n=1465) | |||||||
| Age-corrected RTL quartiles | Model 1 HR (95%CI) | P | Model 2 HR (95%CI) | P | Model 3 HR (95%CI) | P | |
| 1st (<0.0140) (n=377) | 126 (33%) / 251 (67%) | Ref. | Ref. | Ref. | |||
| 2nd - 3rd(0.0141-0.0509) (n=722) | 196 (27%) / 526 (73%) | 0.79 (0.63-0.99) | 0.037 | 0.84 (0.65-1.08) | 0.169 | 0.78 (0.60-1.01) | 0.061 |
| 4th (>0.0510) (n=366) | 92 (25%) / 274 (75%) | 0.70 (0.54-0.92) | 0.011 | 0.80 (0.59-1.09) | 0.156 | 0.82 (0.60-1.13) | 0.223 |
| (C) 4th quartile of B12 (n=749) | |||||||
| Age-corrected RTL quartiles | Model 1 HR (95%CI) | P | Model 2 HR (95%CI) | P | Model 3 HR (95%CI) | P | |
| 1st (<0.0140) (HB12ST) (n=169) | 70 (41%) / 99 (59%) | Ref. | Ref. | Ref. | |||
| 2nd - 3rd(0.0141-0.0509) (n=377) | 132 (35%) / 245 (65%) | 0.83 (0.62-1.11) | 0.209 | 0.86 (0.61-1.20) | 0.368 | 0.87 (0.60-1.24) | 0.434 |
| 4th (>0.0510) (HB12LT) (n=203) | 39 (19%) / 164 (81%) | 0.40 (0.27-0.59) | <0.001 | 0.51 (0.33-0.79) | 0.003 | 0.62 (0.39-0.98) | 0.040 |
Model 1: crude model. Model 2: adjusted for IL-6, hsCRP, albumin, total bilirubin, GOT, GPT, GGT, ALP, HCY, vitamin B6 and folate. Model 3: as model 2 plus sex, LDL-C, HDL-C, BMI, blood pressure, diabetes mellitus, smoking, CAD, MI, stroke, PVD, acute infection, creatinine, TSH, ace-inhibitor, lipid lowering therapy, aspirin/other antiplatelet agents, beta blockers, vitamin K antagonist, diuretics, thyroid therapy, vitamin supplementation, Friesinger Score, Gensini. Score. Ref.: reference.
Statistically significant differences are reported in bold.